Search | Clinical Trials Finder

Conditions: Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions: CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 16
States / cities: Birmingham, Alabama • Davis, California • Miami, Florida + 12 more

Conditions: Down Syndrome, Cerebral Palsy, Apraxia of Speech, Speech Sound Disorder, Speech Disorders in Children, Speech and Language Disorder
Interventions: AAC Generative Language Intervention; Behavioral
Lead sponsor: University of Central Florida; Other
Eligibility: 42 Months to 60 Months
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Down Syndrome
Interventions: Placebo, RG1662; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 5 more

Conditions: Autism Spectrum Disorder, Down Syndrome
Interventions: Bicycle Training Intervention; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 9 Years to 18 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Southbend, Indiana • Ann Arbor, Michigan • Grand Rapids, Michigan

Conditions: Leukemia, Down Syndrome
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Down Syndrome
Interventions: Not listed
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 30 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Tucson, Arizona • Durham, North Carolina

Conditions: Developmental Disability, Autism Spectrum Disorder, Down Syndrome, Cerebral Palsy
Interventions: Zumba High Tempo, Zumba Low Tempo; Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Opioid Withdrawal
Interventions: Lofexidine; Drug
Lead sponsor: USWM, LLC (dba US WorldMeds); Industry
Eligibility: 18 Years and older
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 18
States / cities: Little Rock, Arkansas • Springdale, Arkansas • San Diego, California + 15 more

Conditions: Down Syndrome, Adaptive Behavior, Quality of Life
Interventions: The MapHabit System; Device
Lead sponsor: MapHabit, Inc.; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Down Syndrome, Polyendocrinopathies, Autoimmune, Respiratory Tract Infections, Autoimmunity
Interventions: Phlebotomy; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 22 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Down Syndrome, Congenital Heart Disease
Interventions: Stanford Binet Intelligence Scales, Fifth Edition, Vineland Adaptive Behavior Scales Third Edition, Peabody Picture Vocabulary Test, Fifth Edition, Expressive Vocabulary Test, Third Edition, Leiter International Performance Scale, Third Edition, Social Communication Questionnaire, Current Form, Aberrant Behavior Checklist, Repetitive Behavior Scale, Revised; Other
Lead sponsor: Carelon Research; Other
Eligibility: 60 Months to 155 Months
Enrollment: 273 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 13
States / cities: Wilmington, Delaware • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more

Conditions: Down Syndrome
Interventions: Skeletal Status Assessment of a Down Syndrome Population; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Chromosome 13 Aneuploidy, Chromosome 18 Aneuploidy, Chromosome 21 Aneuploidy, Sex Chromosome Aberrations, Other Microdeletions
Interventions: Blood draw, Cheek swab/Saliva Sampling; Procedure
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,781 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Trisomy 13, Trisomy 18, Trisomy 21, Sex Chromosome Abnormalities
Interventions: Not listed
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 6
States / cities: San Carlos, California • San Diego, California • New York, New York + 2 more

Conditions: Down Syndrome, Obstructive Sleep Apnea
Interventions: Inspire Upper Airway Stimulation (UAS) System; Device
Lead sponsor: Inspire Medical Systems, Inc.; Industry
Eligibility: 10 Years to 21 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 8
States / cities: Atlanta, Georgia • Boston, Massachusetts • Cincinnati, Ohio + 5 more

Conditions: Down Syndrome
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years and older
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Down Syndrome
Interventions: Promoting Health through Parent Empowerment and the Activation of Routines, Enhanced Usual Care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Months and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypothyroidism, Trisomy 21
Interventions: Liquid stable levothyroxine (L-T4) Tirosint-SOL, Oral tablet levothyroxine (L-T4); Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 2 Months to 4 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Adolescent Behavior, Intellectual Disability, Down Syndrome, Physical Activity
Interventions: Group Exercise Sessions, Individual Support Sessions, Facebook Group; Behavioral
Lead sponsor: University of Kansas; Other
Eligibility: 10 Years to 21 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Lawrence, Kansas

Conditions: Down Syndrome, Subclinical Hypothyroidism
Interventions: Levothyroxine; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 8 Years to 20 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Philadelphia, Pennsylvania

Conditions: Down Syndrome
Interventions: Exercise; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 10 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Vanishing Twin, Trisomy 21, Trisomy 13, Trisomy 18
Interventions: Not listed
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 21
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 15 more

Conditions: Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome, Myeloid Leukemia Associated With Down Syndrome, Myeloproliferative Neoplasm
Interventions: Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine, Daunorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Thioguanine; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 91 Days to 3 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 169
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 131 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
Interventions: Biospecimen Collection; Procedure
Lead sponsor: PedAL BCU, LLC; Other
Eligibility: Up to 22 Years
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 164
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 133 more

Search by objective public record fields.

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

Measuring Aided Language Development

A Study of RG1662 in Individuals With Down Syndrome

A Bicycle Training Intervention

Neurocognitive and Psychosocial Outcomes in Survivors of Childhood Leukemia With Down Syndrome

A Non-Drug Study of The Suitability of Neurocognitive Tests And Functioning Scales For The Measurement of Cognitive And Functioning Changes in Individuals With Down Syndrome

The Effects of Virtual Zumba® in Individuals With Developmental Disabilities

Open-Label, Safety Study of Lofexidine

Life Skills Improved in Children With Down Syndrome After Using Assistive Technology

Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome

Congenital Heart Disease: Impact on Learning and Development in Down Syndrome (CHILD-DS)

Assessment of Bone Density and Bone Turnover Markers in Patients With Down Syndrome and Comparison to the Ts65Dn Model

Non-invasive Prenatal Diagnostic Validation Study

Multiple Gestation Study

Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea

The Experience of Caregivers of Children With Down Syndrome

Promoting Health Through Parent Empowerment and the Activation of Routines (PrO-PEAR)

Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients

Promotion of Physical Activity in Adolescents With Intellectual and Developmental Disabilities

Treatment Trial of Subclinical Hypothyroidism in Down Syndrome

The Impact of an 8-week Supported Exercise Program on Fitness and Symptoms in Adolescents With Down Syndrome

Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study